Europe Diabetes Pen Market Share

Europe, the Middle East and Africa Diabetes Pen Market Overview

Europe, the Middle East and Africa Diabetes Pen Market Size was valued at USD 16.34 billion in 2022 and is projected to grow from USD 16.96 Billion in 2023 to USD 29.30 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.90% during the forecast period (2023 - 2032). The increasing prevalence of diabetes among people of all ages is a significant contributor to the rising demand for diabetes pens. In addition, their straightforward operation and accuracy in terms of insulin dosage promote the Diabetes Pen Market in Europe, the Middle East, and Africa.

Europe, the Middle East and Africa Diabetes Pen Market Trends

Technological Advancements in the Industry to Drive the Market Growth

To regulate insulin, diabetic patients use an insulin pen or injection pen. It is a simple and convenient method for administering insulin via injection. It eliminates the need to hold the vial and syringe, allowing patients to administer insulin in the workplace or at school for their children. It requires significantly less time than syringes. There are two types of insulin syringes on the market: disposable and reusable. Diabetes pen improves quality of life and decreases hyperglycemia-related anxiety. Diabetes is becoming more prevalent, which has increased the demand for Diabetes pens. Diabetes pens are administered concurrently with the growing demand for insulin pens among diabetics. These devices used in conjunction with insulin syringes aid in administering the medication to the subject. Massive technological advancements also contribute to the expansion of the Diabetes pen market.

Consumer Preference for Insulin Pens as Drug Delivery System

Increasing use of innovative, reusable injection devices by diabetic patients is a further factor propelling the market forward. In addition, the growing prevalence of automated injection pens is a significant factor in the market expansion of injection pens. Due to their simplicity of use, precision, safety, and convenience in medication delivery, automated injection instruments are increasingly utilized by medical personnel. Injection pens are in high demand all over the world, not just in affluent nations where the geriatric population is at an increased risk for diseases such as diabetes and cancer. These elements are responsible for the expansion of the market.

Diabetes pens should not be shared due to the risk of disease transmission, including hepatitis B. Diabetes pen needles with reduced lengths can be used with ease by all patients, including those who are overweight. These factors have positively anticipated propelling the development of the Europe, the Middle East and Africa Diabetes Pen Market.

However, there are certain constraints and limitations that will impede the expansion of the Europe, the Middle East and Africa Diabetes Pen Market as a whole. Two types of insulin cannot be mixed in an insulin pen, thereby increasing the required injection frequency, which, in turn, inhibits the market's growth.

EME and Africa Diabetes Pen Market Segment Insights

Europe, the Middle East and Africa Diabetes Pen Type Insights

The market, based on type, has been bifurcated into Disposable insulin pen, and reusable insulin pen. The reusable variable has the highest CAGR as a result of the rising demand for diabetic patients and the growing awareness of self-administration of insulin. The affordability of reusable insulins also contributes to the market expansion.

EME and Africa Diabetes Pen Therapy Insights

The market, based on type, has been segmented into Insulin, Glucagon-Like Peptide-1 (Glp-1), Growth Hormones.

Europe, the Middle East and Africa Diabetes Pen Regional Insights

The market, based on region, has been focused on Europe, and Middle East and Africa regions.

Europe is the largest market in the world and is anticipated to experience negligible expansion over the forecast period. This article attributes the development of the region to the widespread use of diabetes pens in the United Kingdom. In addition, the implementation of aggressive market penetration strategies by major market participants is anticipated to result in a rise in insulin pen adoption in the region over the forecast period.

Due to rising consumer awareness of lifestyle-related diseases and the emergence of an inundation of preventative measures to combat the elevated sugar levels of individuals, the Middle East and Africa region is anticipated to experience constant and respectable growth. Due to the high prevalence of obese and overweight citizens, the incidence of diabetes in Saudi Arabia is rising significantly and is anticipated to remain high in the coming years. Iran, the second-largest country in the Middle East, has a significant diabetes problem due to its high prevalence rate, rising incidence rate, and economic impact. In Iran, diabetes-related mortality continues to rise; the age-adjusted fatality rate from diabetes has increased over time. Diabetes has significant economic ramifications for the nation. In addition to its high direct healthcare expenses, diabetes is a major risk factor for other chronic diseases, such as cardiovascular disease.

Europe, the Middle East and Africa Diabetes Pen Key Market Players & Competitive Insights

As time progresses, the competitive landscape expands as individuals acquire novel and superior products that can generate market value.  The increasing prevalence of diabetes and favorable reimbursement scenario for pen needles, federal initiatives to raise awareness about injection techniques, increasing market penetration by leading players, the development of enhanced pen needle technologies, and ongoing projects will stimulate the market.

Key Companies in the Europe, the Middle East and Africa diabetes pen market include

• Becton, Dickinson And Company


• Novo Nordisk A/S


• Ypsomed Holding Ag


• Owen Mumford. Ltd


• Sanofi


• Eli Lilly


• Merck Animal Health

Europe, the Middle East and Africa Diabetes Pen Industry Developments

July 2023: Injector pens for the low-cost insulins produced by Civica, Inc. was manufactured and supplied by Ypsomed AG beginning in July 2023.  Prior to this announcement, Civica stated that it planned to manufacture three insulin biosimilars: glargine, lispro, and aspart. Both vials and prefilled pens will be made available for purchase. The business hopes to sell the insulins at far lower prices than the competition. Civica will be able to help make self-administered treatment more affordable for Americans with diabetes with the assistance of Ypsomed, a recognized injectable device specialist with over 35 years of experience.